|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM181152134 |
| 003 |
DE-627 |
| 005 |
20231223160733.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231223s2008 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2008.06.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0604.xml
|
| 035 |
|
|
|a (DE-627)NLM181152134
|
| 035 |
|
|
|a (NLM)18653385
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Hedegaard, Chris J
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis
|
| 264 |
|
1 |
|c 2008
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.10.2008
|
| 500 |
|
|
|a Date Revised 15.11.2012
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Interferon (IFN)-beta therapy has well-established clinical benefits in multiple sclerosis (MS), but the underlying modulation of cytokine responses to myelin self-antigens remains poorly understood. We analysed the CD4+ T cell proliferation and cytokine responses elicited by myelin basic protein (MBP) and a foreign recall antigen, tetanus toxoid (TT), in mononuclear cell cultures from fourteen MS patients undergoing IFN-beta therapy. The MBP-elicited IFN-gamma-, TNF-alpha- and IL-10 production decreased during therapy (p<0.007-0.03), while the IL-6 production increased (p<0.03). No significant change was observed in the MBP-induced CD4+ T cell proliferation, or in the production of IL-4, IL-5 and brain-derived neurotrophic factor. In comparison, IFN-beta therapy reduced IFN-gamma and IL-4 responses to TT (p<0.003 and p<0.04). Thus, IFN-beta inhibits IFN-gamma production in general, presumably alleviating the detrimental influence of IFN-gamma in MS. However, the increase in proinflammatory IL-6 and the decrease in anti-inflammatory IL-10 responses suggest that IFN-beta has more diverse effects than previously assumed
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Myelin Basic Protein
|2 NLM
|
| 650 |
|
7 |
|a Tetanus Toxoid
|2 NLM
|
| 650 |
|
7 |
|a Interferon-beta
|2 NLM
|
| 650 |
|
7 |
|a 77238-31-4
|2 NLM
|
| 700 |
1 |
|
|a Krakauer, Martin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bendtzen, Klaus
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sørensen, Per Soelberg
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sellebjerg, Finn
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nielsen, Claus H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 129(2008), 1 vom: 18. Okt., Seite 80-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:129
|g year:2008
|g number:1
|g day:18
|g month:10
|g pages:80-9
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2008.06.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 129
|j 2008
|e 1
|b 18
|c 10
|h 80-9
|